Advanced Enzyme Technologies Limited has informed the Exchange about Incorporation
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Advanced Enzyme Technologies' board, meeting on May 13, 2025, approved audited financial results for FY25 with consolidated revenue from operations of ₹6,369.1 million (vs ₹6,238.7 million in FY24) and consolidated net profit of ₹1,339.7 million (slightly lower than ₹1,369.5 million in FY24). Standalone revenue stood at ₹3,514.1 million with net profit of ₹1,024.2 million. The board declared an interim dividend of ₹4 per share (200%) for FY26 with a record date of May 17, 2025, and recommended a final dividend of ₹1.20 per share (60%) for FY25, subject to shareholder approval at the 36th AGM on July 30, 2025. The board also approved the incorporation of a new private company as a wholly-owned subsidiary in India, and appointed Mr. Shiv Hari Jalan as Secretarial Auditor for five years. Auditors MSKA & Associates issued an unmodified opinion on the financials.
Total dividend of ₹5.20 per share for FY25 offers a healthy yield, while flat-to-marginal earnings growth and the new subsidiary incorporation signal steady but not breakout performance, likely to be viewed neutrally by investors.